Global Nanomaterial-Based Adjuvants Vaccine Supply, Demand and Key Producers, 2024-2030

Description

Nanoparticles (NPs) can act as adjuvants for vaccines, hence they are referred to as a nano-adjuvant (NA). NPs can either encapsulate or adsorb the vaccine antigen or DNA in an appropriate formulation, thus increasing stability, cellular uptake, and immunogenicity.

The global Nanomaterial-Based Adjuvants Vaccine market size is expected to reach $ 576890 million by 2030, rising at a market growth of 9.4% CAGR during the forecast period (2024-2030).

Global key players of Nanomaterial-Based Adjuvants Vaccine include Emergent BioSolutions, Sanofi, etc. Global top 3 companies hold a share over 80%. North America is the largest market, with a share about 60%, followed by Europe and Japan with the share about 20% and 5%. In terms of product, Lipidosome is the largest segment, with a share about 80%. And in terms of application, the largest application is SARS-CoV-2, with a share about 75%.

Technological advancements in nanomaterial-based adjuvants vaccines are an important factor driving market development. Nano-adjuvants have the advantages of good biocompatibility, biological targeting, sustained release, safety and high efficiency, and can significantly improve the immunogenicity and protective effect of vaccines. With the continuous development and application of nanotechnology, the types and performance of nanomaterial-based adjuvants vaccines will be further improved to meet the needs of more disease prevention. As the market continues to expand and potential competitors join, competition in the nanomaterial-based adjuvants vaccines market will become more intense. Overall, the nanomaterial-based adjuvants vaccines market has broad prospects. With the advancement of technology and the increase in market demand, the market size is expected to continue to grow in the next few years.

This report studies the global Nanomaterial-Based Adjuvants Vaccine production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Nanomaterial-Based Adjuvants Vaccine and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Nanomaterial-Based Adjuvants Vaccine that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Nanomaterial-Based Adjuvants Vaccine total production and demand, 2019-2030, (M Doses)
Global Nanomaterial-Based Adjuvants Vaccine total production value, 2019-2030, (USD Million)
Global Nanomaterial-Based Adjuvants Vaccine production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (M Doses), (based on production site)
Global Nanomaterial-Based Adjuvants Vaccine consumption by region & country, CAGR, 2019-2030 & (M Doses)
U.S. VS China: Nanomaterial-Based Adjuvants Vaccine domestic production, consumption, key domestic manufacturers and share
Global Nanomaterial-Based Adjuvants Vaccine production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (M Doses)
Global Nanomaterial-Based Adjuvants Vaccine production by Type, production, value, CAGR, 2019-2030, (USD Million) & (M Doses)
Global Nanomaterial-Based Adjuvants Vaccine production by Application, production, value, CAGR, 2019-2030, (USD Million) & (M Doses)
This report profiles key players in the global Nanomaterial-Based Adjuvants Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Emergent BioSolutions, Sanofi, GlaxoSmithKline Biologicals, Merck, Pfizer, Novartis, Moderna, Jiangsu Recbio Technology, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Nanomaterial-Based Adjuvants Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (M Doses) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Nanomaterial-Based Adjuvants Vaccine Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Nanomaterial-Based Adjuvants Vaccine Market, Segmentation by Type:
    Aluminium Hydroxides
    Aluminium Phosphate
    Lipidosome
    Others

Global Nanomaterial-Based Adjuvants Vaccine Market, Segmentation by Application:
    Pneumococcus
    Human Papilloma Virus
    DTaP
    Viral Hepatitis TypeA
    Viral Hepatitis TypeB
    SARS-CoV-2
    Others

Companies Profiled:
    Emergent BioSolutions
    Sanofi
    GlaxoSmithKline Biologicals
    Merck
    Pfizer
    Novartis
    Moderna
    Jiangsu Recbio Technology

Key Questions Answered:
1. How big is the global Nanomaterial-Based Adjuvants Vaccine market?
2. What is the demand of the global Nanomaterial-Based Adjuvants Vaccine market?
3. What is the year over year growth of the global Nanomaterial-Based Adjuvants Vaccine market?
4. What is the production and production value of the global Nanomaterial-Based Adjuvants Vaccine market?
5. Who are the key producers in the global Nanomaterial-Based Adjuvants Vaccine market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Nanomaterial-Based Adjuvants Vaccine Introduction
    1.2 World Nanomaterial-Based Adjuvants Vaccine Supply & Forecast
        1.2.1 World Nanomaterial-Based Adjuvants Vaccine Production Value (2019 & 2023 & 2030)
        1.2.2 World Nanomaterial-Based Adjuvants Vaccine Production (2019-2030)
        1.2.3 World Nanomaterial-Based Adjuvants Vaccine Pricing Trends (2019-2030)
    1.3 World Nanomaterial-Based Adjuvants Vaccine Production by Region (Based on Production Site)
        1.3.1 World Nanomaterial-Based Adjuvants Vaccine Production Value by Region (2019-2030)
        1.3.2 World Nanomaterial-Based Adjuvants Vaccine Production by Region (2019-2030)
        1.3.3 World Nanomaterial-Based Adjuvants Vaccine Average Price by Region (2019-2030)
        1.3.4 North America Nanomaterial-Based Adjuvants Vaccine Production (2019-2030)
        1.3.5 Europe Nanomaterial-Based Adjuvants Vaccine Production (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Nanomaterial-Based Adjuvants Vaccine Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Nanomaterial-Based Adjuvants Vaccine Major Market Trends

2 Demand Summary
    2.1 World Nanomaterial-Based Adjuvants Vaccine Demand (2019-2030)
    2.2 World Nanomaterial-Based Adjuvants Vaccine Consumption by Region
        2.2.1 World Nanomaterial-Based Adjuvants Vaccine Consumption by Region (2019-2024)
        2.2.2 World Nanomaterial-Based Adjuvants Vaccine Consumption Forecast by Region (2025-2030)
    2.3 United States Nanomaterial-Based Adjuvants Vaccine Consumption (2019-2030)
    2.4 China Nanomaterial-Based Adjuvants Vaccine Consumption (2019-2030)
    2.5 Europe Nanomaterial-Based Adjuvants Vaccine Consumption (2019-2030)
    2.6 Japan Nanomaterial-Based Adjuvants Vaccine Consumption (2019-2030)
    2.7 South Korea Nanomaterial-Based Adjuvants Vaccine Consumption (2019-2030)
    2.8 ASEAN Nanomaterial-Based Adjuvants Vaccine Consumption (2019-2030)
    2.9 India Nanomaterial-Based Adjuvants Vaccine Consumption (2019-2030)

3 World Manufacturers Competitive Analysis
    3.1 World Nanomaterial-Based Adjuvants Vaccine Production Value by Manufacturer (2019-2024)
    3.2 World Nanomaterial-Based Adjuvants Vaccine Production by Manufacturer (2019-2024)
    3.3 World Nanomaterial-Based Adjuvants Vaccine Average Price by Manufacturer (2019-2024)
    3.4 Nanomaterial-Based Adjuvants Vaccine Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Nanomaterial-Based Adjuvants Vaccine Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Nanomaterial-Based Adjuvants Vaccine in 2023
        3.5.3 Global Concentration Ratios (CR8) for Nanomaterial-Based Adjuvants Vaccine in 2023
    3.6 Nanomaterial-Based Adjuvants Vaccine Market: Overall Company Footprint Analysis
        3.6.1 Nanomaterial-Based Adjuvants Vaccine Market: Region Footprint
        3.6.2 Nanomaterial-Based Adjuvants Vaccine Market: Company Product Type Footprint
        3.6.3 Nanomaterial-Based Adjuvants Vaccine Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Nanomaterial-Based Adjuvants Vaccine Production Value Comparison
        4.1.1 United States VS China: Nanomaterial-Based Adjuvants Vaccine Production Value Comparison (2019 & 2023 & 2030)
        4.1.2 United States VS China: Nanomaterial-Based Adjuvants Vaccine Production Value Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States VS China: Nanomaterial-Based Adjuvants Vaccine Production Comparison
        4.2.1 United States VS China: Nanomaterial-Based Adjuvants Vaccine Production Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Nanomaterial-Based Adjuvants Vaccine Production Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States VS China: Nanomaterial-Based Adjuvants Vaccine Consumption Comparison
        4.3.1 United States VS China: Nanomaterial-Based Adjuvants Vaccine Consumption Comparison (2019 & 2023 & 2030)
        4.3.2 United States VS China: Nanomaterial-Based Adjuvants Vaccine Consumption Market Share Comparison (2019 & 2023 & 2030)
    4.4 United States Based Nanomaterial-Based Adjuvants Vaccine Manufacturers and Market Share, 2019-2024
        4.4.1 United States Based Nanomaterial-Based Adjuvants Vaccine Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production Value (2019-2024)
        4.4.3 United States Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production (2019-2024)
    4.5 China Based Nanomaterial-Based Adjuvants Vaccine Manufacturers and Market Share
        4.5.1 China Based Nanomaterial-Based Adjuvants Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production Value (2019-2024)
        4.5.3 China Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production (2019-2024)
    4.6 Rest of World Based Nanomaterial-Based Adjuvants Vaccine Manufacturers and Market Share, 2019-2024
        4.6.1 Rest of World Based Nanomaterial-Based Adjuvants Vaccine Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production Value (2019-2024)
        4.6.3 Rest of World Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production (2019-2024)

5 Market Analysis by Type
    5.1 World Nanomaterial-Based Adjuvants Vaccine Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Aluminium Hydroxides
        5.2.2 Aluminium Phosphate
        5.2.3 Lipidosome
        5.2.4 Others
    5.3 Market Segment by Type
        5.3.1 World Nanomaterial-Based Adjuvants Vaccine Production by Type (2019-2030)
        5.3.2 World Nanomaterial-Based Adjuvants Vaccine Production Value by Type (2019-2030)
        5.3.3 World Nanomaterial-Based Adjuvants Vaccine Average Price by Type (2019-2030)

6 Market Analysis by Application
    6.1 World Nanomaterial-Based Adjuvants Vaccine Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Pneumococcus
        6.2.2 Human Papilloma Virus
        6.2.3 DTaP
        6.2.4 Viral Hepatitis TypeA
        6.2.5 Viral Hepatitis TypeB
        6.2.6 SARS-CoV-2
        6.2.7 Others
    6.3 Market Segment by Application
        6.3.1 World Nanomaterial-Based Adjuvants Vaccine Production by Application (2019-2030)
        6.3.2 World Nanomaterial-Based Adjuvants Vaccine Production Value by Application (2019-2030)
        6.3.3 World Nanomaterial-Based Adjuvants Vaccine Average Price by Application (2019-2030)

7 Company Profiles
    7.1 Emergent BioSolutions
        7.1.1 Emergent BioSolutions Details
        7.1.2 Emergent BioSolutions Major Business
        7.1.3 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product and Services
        7.1.4 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.1.5 Emergent BioSolutions Recent Developments/Updates
        7.1.6 Emergent BioSolutions Competitive Strengths & Weaknesses
    7.2 Sanofi
        7.2.1 Sanofi Details
        7.2.2 Sanofi Major Business
        7.2.3 Sanofi Nanomaterial-Based Adjuvants Vaccine Product and Services
        7.2.4 Sanofi Nanomaterial-Based Adjuvants Vaccine Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.2.5 Sanofi Recent Developments/Updates
        7.2.6 Sanofi Competitive Strengths & Weaknesses
    7.3 GlaxoSmithKline Biologicals
        7.3.1 GlaxoSmithKline Biologicals Details
        7.3.2 GlaxoSmithKline Biologicals Major Business
        7.3.3 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product and Services
        7.3.4 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.3.5 GlaxoSmithKline Biologicals Recent Developments/Updates
        7.3.6 GlaxoSmithKline Biologicals Competitive Strengths & Weaknesses
    7.4 Merck
        7.4.1 Merck Details
        7.4.2 Merck Major Business
        7.4.3 Merck Nanomaterial-Based Adjuvants Vaccine Product and Services
        7.4.4 Merck Nanomaterial-Based Adjuvants Vaccine Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.4.5 Merck Recent Developments/Updates
        7.4.6 Merck Competitive Strengths & Weaknesses
    7.5 Pfizer
        7.5.1 Pfizer Details
        7.5.2 Pfizer Major Business
        7.5.3 Pfizer Nanomaterial-Based Adjuvants Vaccine Product and Services
        7.5.4 Pfizer Nanomaterial-Based Adjuvants Vaccine Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.5.5 Pfizer Recent Developments/Updates
        7.5.6 Pfizer Competitive Strengths & Weaknesses
    7.6 Novartis
        7.6.1 Novartis Details
        7.6.2 Novartis Major Business
        7.6.3 Novartis Nanomaterial-Based Adjuvants Vaccine Product and Services
        7.6.4 Novartis Nanomaterial-Based Adjuvants Vaccine Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.6.5 Novartis Recent Developments/Updates
        7.6.6 Novartis Competitive Strengths & Weaknesses
    7.7 Moderna
        7.7.1 Moderna Details
        7.7.2 Moderna Major Business
        7.7.3 Moderna Nanomaterial-Based Adjuvants Vaccine Product and Services
        7.7.4 Moderna Nanomaterial-Based Adjuvants Vaccine Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.7.5 Moderna Recent Developments/Updates
        7.7.6 Moderna Competitive Strengths & Weaknesses
    7.8 Jiangsu Recbio Technology
        7.8.1 Jiangsu Recbio Technology Details
        7.8.2 Jiangsu Recbio Technology Major Business
        7.8.3 Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Product and Services
        7.8.4 Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.8.5 Jiangsu Recbio Technology Recent Developments/Updates
        7.8.6 Jiangsu Recbio Technology Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Nanomaterial-Based Adjuvants Vaccine Industry Chain
    8.2 Nanomaterial-Based Adjuvants Vaccine Upstream Analysis
        8.2.1 Nanomaterial-Based Adjuvants Vaccine Core Raw Materials
        8.2.2 Main Manufacturers of Nanomaterial-Based Adjuvants Vaccine Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Nanomaterial-Based Adjuvants Vaccine Production Mode
    8.6 Nanomaterial-Based Adjuvants Vaccine Procurement Model
    8.7 Nanomaterial-Based Adjuvants Vaccine Industry Sales Model and Sales Channels
        8.7.1 Nanomaterial-Based Adjuvants Vaccine Sales Model
        8.7.2 Nanomaterial-Based Adjuvants Vaccine Typical Distributors

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
 Table 1. World Nanomaterial-Based Adjuvants Vaccine Production Value by Region (2019, 2023 and 2030) & (USD Million)
 Table 2. World Nanomaterial-Based Adjuvants Vaccine Production Value by Region (2019-2024) & (USD Million)
 Table 3. World Nanomaterial-Based Adjuvants Vaccine Production Value by Region (2025-2030) & (USD Million)
 Table 4. World Nanomaterial-Based Adjuvants Vaccine Production Value Market Share by Region (2019-2024)
 Table 5. World Nanomaterial-Based Adjuvants Vaccine Production Value Market Share by Region (2025-2030)
 Table 6. World Nanomaterial-Based Adjuvants Vaccine Production by Region (2019-2024) & (M Doses)
 Table 7. World Nanomaterial-Based Adjuvants Vaccine Production by Region (2025-2030) & (M Doses)
 Table 8. World Nanomaterial-Based Adjuvants Vaccine Production Market Share by Region (2019-2024)
 Table 9. World Nanomaterial-Based Adjuvants Vaccine Production Market Share by Region (2025-2030)
 Table 10. World Nanomaterial-Based Adjuvants Vaccine Average Price by Region (2019-2024) & (US$/Dose)
 Table 11. World Nanomaterial-Based Adjuvants Vaccine Average Price by Region (2025-2030) & (US$/Dose)
 Table 12. Nanomaterial-Based Adjuvants Vaccine Major Market Trends
 Table 13. World Nanomaterial-Based Adjuvants Vaccine Consumption Growth Rate Forecast by Region (2019 & 2023 & 2030) & (M Doses)
 Table 14. World Nanomaterial-Based Adjuvants Vaccine Consumption by Region (2019-2024) & (M Doses)
 Table 15. World Nanomaterial-Based Adjuvants Vaccine Consumption Forecast by Region (2025-2030) & (M Doses)
 Table 16. World Nanomaterial-Based Adjuvants Vaccine Production Value by Manufacturer (2019-2024) & (USD Million)
 Table 17. Production Value Market Share of Key Nanomaterial-Based Adjuvants Vaccine Producers in 2023
 Table 18. World Nanomaterial-Based Adjuvants Vaccine Production by Manufacturer (2019-2024) & (M Doses)
 Table 19. Production Market Share of Key Nanomaterial-Based Adjuvants Vaccine Producers in 2023
 Table 20. World Nanomaterial-Based Adjuvants Vaccine Average Price by Manufacturer (2019-2024) & (US$/Dose)
 Table 21. Global Nanomaterial-Based Adjuvants Vaccine Company Evaluation Quadrant
 Table 22. World Nanomaterial-Based Adjuvants Vaccine Industry Rank of Major Manufacturers, Based on Production Value in 2023
 Table 23. Head Office and Nanomaterial-Based Adjuvants Vaccine Production Site of Key Manufacturer
 Table 24. Nanomaterial-Based Adjuvants Vaccine Market: Company Product Type Footprint
 Table 25. Nanomaterial-Based Adjuvants Vaccine Market: Company Product Application Footprint
 Table 26. Nanomaterial-Based Adjuvants Vaccine Competitive Factors
 Table 27. Nanomaterial-Based Adjuvants Vaccine New Entrant and Capacity Expansion Plans
 Table 28. Nanomaterial-Based Adjuvants Vaccine Mergers & Acquisitions Activity
 Table 29. United States VS China Nanomaterial-Based Adjuvants Vaccine Production Value Comparison, (2019 & 2023 & 2030) & (USD Million)
 Table 30. United States VS China Nanomaterial-Based Adjuvants Vaccine Production Comparison, (2019 & 2023 & 2030) & (M Doses)
 Table 31. United States VS China Nanomaterial-Based Adjuvants Vaccine Consumption Comparison, (2019 & 2023 & 2030) & (M Doses)
 Table 32. United States Based Nanomaterial-Based Adjuvants Vaccine Manufacturers, Headquarters and Production Site (States, Country)
 Table 33. United States Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production Value, (2019-2024) & (USD Million)
 Table 34. United States Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production Value Market Share (2019-2024)
 Table 35. United States Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production (2019-2024) & (M Doses)
 Table 36. United States Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production Market Share (2019-2024)
 Table 37. China Based Nanomaterial-Based Adjuvants Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
 Table 38. China Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production Value, (2019-2024) & (USD Million)
 Table 39. China Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production Value Market Share (2019-2024)
 Table 40. China Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production, (2019-2024) & (M Doses)
 Table 41. China Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production Market Share (2019-2024)
 Table 42. Rest of World Based Nanomaterial-Based Adjuvants Vaccine Manufacturers, Headquarters and Production Site (State, Country)
 Table 43. Rest of World Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production Value, (2019-2024) & (USD Million)
 Table 44. Rest of World Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production Value Market Share (2019-2024)
 Table 45. Rest of World Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production, (2019-2024) & (M Doses)
 Table 46. Rest of World Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production Market Share (2019-2024)
 Table 47. World Nanomaterial-Based Adjuvants Vaccine Production Value by Type, (USD Million), 2019 & 2023 & 2030
 Table 48. World Nanomaterial-Based Adjuvants Vaccine Production by Type (2019-2024) & (M Doses)
 Table 49. World Nanomaterial-Based Adjuvants Vaccine Production by Type (2025-2030) & (M Doses)
 Table 50. World Nanomaterial-Based Adjuvants Vaccine Production Value by Type (2019-2024) & (USD Million)
 Table 51. World Nanomaterial-Based Adjuvants Vaccine Production Value by Type (2025-2030) & (USD Million)
 Table 52. World Nanomaterial-Based Adjuvants Vaccine Average Price by Type (2019-2024) & (US$/Dose)
 Table 53. World Nanomaterial-Based Adjuvants Vaccine Average Price by Type (2025-2030) & (US$/Dose)
 Table 54. World Nanomaterial-Based Adjuvants Vaccine Production Value by Application, (USD Million), 2019 & 2023 & 2030
 Table 55. World Nanomaterial-Based Adjuvants Vaccine Production by Application (2019-2024) & (M Doses)
 Table 56. World Nanomaterial-Based Adjuvants Vaccine Production by Application (2025-2030) & (M Doses)
 Table 57. World Nanomaterial-Based Adjuvants Vaccine Production Value by Application (2019-2024) & (USD Million)
 Table 58. World Nanomaterial-Based Adjuvants Vaccine Production Value by Application (2025-2030) & (USD Million)
 Table 59. World Nanomaterial-Based Adjuvants Vaccine Average Price by Application (2019-2024) & (US$/Dose)
 Table 60. World Nanomaterial-Based Adjuvants Vaccine Average Price by Application (2025-2030) & (US$/Dose)
 Table 61. Emergent BioSolutions Basic Information, Manufacturing Base and Competitors
 Table 62. Emergent BioSolutions Major Business
 Table 63. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 64. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Production (M Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 65. Emergent BioSolutions Recent Developments/Updates
 Table 66. Emergent BioSolutions Competitive Strengths & Weaknesses
 Table 67. Sanofi Basic Information, Manufacturing Base and Competitors
 Table 68. Sanofi Major Business
 Table 69. Sanofi Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 70. Sanofi Nanomaterial-Based Adjuvants Vaccine Production (M Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 71. Sanofi Recent Developments/Updates
 Table 72. Sanofi Competitive Strengths & Weaknesses
 Table 73. GlaxoSmithKline Biologicals Basic Information, Manufacturing Base and Competitors
 Table 74. GlaxoSmithKline Biologicals Major Business
 Table 75. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 76. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Production (M Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 77. GlaxoSmithKline Biologicals Recent Developments/Updates
 Table 78. GlaxoSmithKline Biologicals Competitive Strengths & Weaknesses
 Table 79. Merck Basic Information, Manufacturing Base and Competitors
 Table 80. Merck Major Business
 Table 81. Merck Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 82. Merck Nanomaterial-Based Adjuvants Vaccine Production (M Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 83. Merck Recent Developments/Updates
 Table 84. Merck Competitive Strengths & Weaknesses
 Table 85. Pfizer Basic Information, Manufacturing Base and Competitors
 Table 86. Pfizer Major Business
 Table 87. Pfizer Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 88. Pfizer Nanomaterial-Based Adjuvants Vaccine Production (M Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 89. Pfizer Recent Developments/Updates
 Table 90. Pfizer Competitive Strengths & Weaknesses
 Table 91. Novartis Basic Information, Manufacturing Base and Competitors
 Table 92. Novartis Major Business
 Table 93. Novartis Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 94. Novartis Nanomaterial-Based Adjuvants Vaccine Production (M Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 95. Novartis Recent Developments/Updates
 Table 96. Novartis Competitive Strengths & Weaknesses
 Table 97. Moderna Basic Information, Manufacturing Base and Competitors
 Table 98. Moderna Major Business
 Table 99. Moderna Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 100. Moderna Nanomaterial-Based Adjuvants Vaccine Production (M Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 101. Moderna Recent Developments/Updates
 Table 102. Moderna Competitive Strengths & Weaknesses
 Table 103. Jiangsu Recbio Technology Basic Information, Manufacturing Base and Competitors
 Table 104. Jiangsu Recbio Technology Major Business
 Table 105. Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 106. Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Production (M Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 107. Jiangsu Recbio Technology Recent Developments/Updates
 Table 108. Jiangsu Recbio Technology Competitive Strengths & Weaknesses
 Table 109. Global Key Players of Nanomaterial-Based Adjuvants Vaccine Upstream (Raw Materials)
 Table 110. Global Nanomaterial-Based Adjuvants Vaccine Typical Customers
 Table 111. Nanomaterial-Based Adjuvants Vaccine Typical Distributors


List of Figures
 Figure 1. Nanomaterial-Based Adjuvants Vaccine Picture
 Figure 2. World Nanomaterial-Based Adjuvants Vaccine Production Value: 2019 & 2023 & 2030, (USD Million)
 Figure 3. World Nanomaterial-Based Adjuvants Vaccine Production Value and Forecast (2019-2030) & (USD Million)
 Figure 4. World Nanomaterial-Based Adjuvants Vaccine Production (2019-2030) & (M Doses)
 Figure 5. World Nanomaterial-Based Adjuvants Vaccine Average Price (2019-2030) & (US$/Dose)
 Figure 6. World Nanomaterial-Based Adjuvants Vaccine Production Value Market Share by Region (2019-2030)
 Figure 7. World Nanomaterial-Based Adjuvants Vaccine Production Market Share by Region (2019-2030)
 Figure 8. North America Nanomaterial-Based Adjuvants Vaccine Production (2019-2030) & (M Doses)
 Figure 9. Europe Nanomaterial-Based Adjuvants Vaccine Production (2019-2030) & (M Doses)
 Figure 10. Nanomaterial-Based Adjuvants Vaccine Market Drivers
 Figure 11. Factors Affecting Demand
 Figure 12. World Nanomaterial-Based Adjuvants Vaccine Consumption (2019-2030) & (M Doses)
 Figure 13. World Nanomaterial-Based Adjuvants Vaccine Consumption Market Share by Region (2019-2030)
 Figure 14. United States Nanomaterial-Based Adjuvants Vaccine Consumption (2019-2030) & (M Doses)
 Figure 15. China Nanomaterial-Based Adjuvants Vaccine Consumption (2019-2030) & (M Doses)
 Figure 16. Europe Nanomaterial-Based Adjuvants Vaccine Consumption (2019-2030) & (M Doses)
 Figure 17. Japan Nanomaterial-Based Adjuvants Vaccine Consumption (2019-2030) & (M Doses)
 Figure 18. South Korea Nanomaterial-Based Adjuvants Vaccine Consumption (2019-2030) & (M Doses)
 Figure 19. ASEAN Nanomaterial-Based Adjuvants Vaccine Consumption (2019-2030) & (M Doses)
 Figure 20. India Nanomaterial-Based Adjuvants Vaccine Consumption (2019-2030) & (M Doses)
 Figure 21. Producer Shipments of Nanomaterial-Based Adjuvants Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2023
 Figure 22. Global Four-firm Concentration Ratios (CR4) for Nanomaterial-Based Adjuvants Vaccine Markets in 2023
 Figure 23. Global Four-firm Concentration Ratios (CR8) for Nanomaterial-Based Adjuvants Vaccine Markets in 2023
 Figure 24. United States VS China: Nanomaterial-Based Adjuvants Vaccine Production Value Market Share Comparison (2019 & 2023 & 2030)
 Figure 25. United States VS China: Nanomaterial-Based Adjuvants Vaccine Production Market Share Comparison (2019 & 2023 & 2030)
 Figure 26. United States VS China: Nanomaterial-Based Adjuvants Vaccine Consumption Market Share Comparison (2019 & 2023 & 2030)
 Figure 27. United States Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production Market Share 2023
 Figure 28. China Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production Market Share 2023
 Figure 29. Rest of World Based Manufacturers Nanomaterial-Based Adjuvants Vaccine Production Market Share 2023
 Figure 30. World Nanomaterial-Based Adjuvants Vaccine Production Value by Type, (USD Million), 2019 & 2023 & 2030
 Figure 31. World Nanomaterial-Based Adjuvants Vaccine Production Value Market Share by Type in 2023
 Figure 32. Aluminium Hydroxides
 Figure 33. Aluminium Phosphate
 Figure 34. Lipidosome
 Figure 35. Others
 Figure 36. World Nanomaterial-Based Adjuvants Vaccine Production Market Share by Type (2019-2030)
 Figure 37. World Nanomaterial-Based Adjuvants Vaccine Production Value Market Share by Type (2019-2030)
 Figure 38. World Nanomaterial-Based Adjuvants Vaccine Average Price by Type (2019-2030) & (US$/Dose)
 Figure 39. World Nanomaterial-Based Adjuvants Vaccine Production Value by Application, (USD Million), 2019 & 2023 & 2030
 Figure 40. World Nanomaterial-Based Adjuvants Vaccine Production Value Market Share by Application in 2023
 Figure 41. Pneumococcus
 Figure 42. Human Papilloma Virus
 Figure 43. DTaP
 Figure 44. Viral Hepatitis TypeA
 Figure 45. Viral Hepatitis TypeB
 Figure 46. SARS-CoV-2
 Figure 47. Others
 Figure 48. World Nanomaterial-Based Adjuvants Vaccine Production Market Share by Application (2019-2030)
 Figure 49. World Nanomaterial-Based Adjuvants Vaccine Production Value Market Share by Application (2019-2030)
 Figure 50. World Nanomaterial-Based Adjuvants Vaccine Average Price by Application (2019-2030) & (US$/Dose)
 Figure 51. Nanomaterial-Based Adjuvants Vaccine Industry Chain
 Figure 52. Nanomaterial-Based Adjuvants Vaccine Procurement Model
 Figure 53. Nanomaterial-Based Adjuvants Vaccine Sales Model
 Figure 54. Nanomaterial-Based Adjuvants Vaccine Sales Channels, Direct Sales, and Distribution
 Figure 55. Methodology
 Figure 56. Research Process and Data Source

Companies Mentioned

Emergent BioSolutions
Sanofi
GlaxoSmithKline Biologicals
Merck
Pfizer
Novartis
Moderna
Jiangsu Recbio Technology